Psoriatic Arthritis | Decision Base | US | 2015
Where Are the Remaining Areas of Opportunity for Emerging Non-TNF Biologics and Oral Agents in the Increasingly Crowded Psoriatic Arthritis Market?
The availability of tumor necrosis factor alpha (TNF-α) inhibitors as therapeutic options has revolutionized the treatment of psoriatic arthritis (PsA). The TNF-α inhibitors have set a high clinical standard (e.g., excellent efficacy in both peripheral and axial PsA, low risk of organ toxicity) that is challenging for emerging therapies to surpass. However, unmet needs exist for improvements in various efficacy, safety and tolerability, and delivery attributes. Several therapies, including those that will offer improvements over the TNF-α inhibitors on delivery or safety have either recently launched, or are in late-stage development. However, within this landscape, significant opportunity exists for new drugs that offer improved efficacy over that of the TNF-α inhibitors.
